Skip to main content

Summary

at Oakland, California and other locations
study started

Description

Summary

This laboratory study is collecting and storing samples of tissue and blood from young patients with Hodgkin's lymphoma. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help the study of cancer in the future.

Official Title

Hodgkin Disease (HD) Banking Study

Details

OBJECTIVES:

I. Establish a biologic specimen repository (of tumor tissue, tissue arrays, lymphoblastoid cell lines, host DNA, tumor and host RNA, serum, and plasma) and database linked to clinical features and outcomes from well-characterized cohorts of children and young adults with Hodgkin's lymphoma.

II. Provide specimens from diagnosis, early response evaluation, completion of chemotherapy and radiotherapy, long-term follow up, and relapse to study prognostic factors for early response, relapse, long-term outcomes, and identification of new biological targets for therapy.

OUTLINE: This is a multicenter study.

Patients enrolled on Hodgkin's lymphoma (HL) therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression.

Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression.

Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation.

Keywords

Refractory Childhood Hodgkin Lymphoma Stage I Childhood Hodgkin Lymphoma Stage II Childhood Hodgkin Lymphoma Stage III Childhood Hodgkin Lymphoma Stage IV Childhood Hodgkin Lymphoma

Eligibility

Inclusion Criteria:

  • Histologically confirmed Hodgkin's lymphoma (HL) meeting 1 of the following criteria:
  • Newly diagnosed, untreated HL (for patients under 22 years of age)
  • Past or present diagnosis of HL and past or present enrollment on a Children's Oncology Group (COG) or legacy HL clinical trial (for patients of any age)

Locations

  • Kaiser Permanente-Oakland
    Oakland, California, 94611, United States
  • Children's Hospital Central California
    Madera, California, 93636-8762, United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California, 95817, United States
  • Sutter General Hospital
    Sacramento, California, 95816, United States
  • Santa Barbara Cottage Hospital
    Santa Barbara, California, 93102, United States
  • Children's Hospital Los Angeles
    Los Angeles, California, 90027, United States
  • Southern California Permanente Medical Group
    Downey, California, 90242, United States
  • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Torrance, California, 90502, United States
  • David Geffen School of Medicine at UCLA
    Los Angeles, California, 90095, United States
  • Mattel Children's Hospital UCLA
    Los Angeles, California, 90095, United States
  • Miller Children's and Women's Hospital Long Beach
    Long Beach, California, 90806, United States
  • Childrens Hospital of Orange County
    Orange, California, 92868, United States
  • Loma Linda University Medical Center
    Loma Linda, California, 92354, United States
  • Summerlin Hospital Medical Center
    Las Vegas, Nevada, 89144, United States
  • University Medical Center of Southern Nevada
    Las Vegas, Nevada, 89102, United States
  • Nevada Cancer Research Foundation CCOP
    Las Vegas, Nevada, 89106, United States
  • Children's Specialty Center of Nevada II
    Las Vegas, Nevada, 89109, United States
  • Sunrise Hospital and Medical Center
    Las Vegas, Nevada, 89109, United States

Details

Status
in progress, not accepting new patients
Start Date
Sponsor
Children's Oncology Group
ID
NCT00900250
Study Type
Observational
Last Updated
May 1, 2017